TR
Markets Editor
Tom Reyes
Covers earnings, deals, financings and the public companies behind therapeutic peptides.
Beats: Markets, GLP-1 · 60 entries on the wire
Challenge: Enabling oral peptide delivery to achieve bioavailability (BAV) in vivo greater than 4%
By Tom ReyesNovo Nordisk (NVO) Sets New 2030 Goals As GLP 1 Competition Builds
By Tom ReyesEli Lilly raises earnings outlook as obesity drug demand drives strong growth, UBS says
By Tom ReyesEarnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
By Tom ReyesDual-Drug Liposomes With YIGSR Peptide Target Breast Tumor Cells in Mice
By Tom ReyesCombined time-restricted feeding and resistance training enhance tirzepatide-induced improvements in adiposity and whole-body insulin sensitivity in female mice
By Tom ReyesHHS eases restrictions on certain unapproved peptides
By Tom ReyesProtagonist Therapeutics (NDQ:PTGX): Can Oral Peptides Disrupt Biologics? Yes, Seriously Peptides!
By Tom ReyesEli Lilly lifts revenue outlook as weight-loss shots offset Foundayo sales miss, shares jump
By Tom ReyesEli Lilly stock jumps as drugmaker raises outlook on booming sales of diabetes and obesity treatments
By Tom ReyesPhysicochemical rule-embedded generative modeling for constrained peptide therapeutics
By Tom ReyesNew peptide policy raises safety concerns over weight-loss drugs
By Tom ReyesEli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion
By Tom ReyesThymosin added to colorectal cancer therapy shows immune signals but evidence falls short
By Tom ReyesPeptides Costa Rica Announces Sponsorship of Professional Boxer Ziggy Myrie Samudio
By Tom ReyesEli Lilly Stocks Rise After Retatrutide's Head-to-Head Trial Results
By Tom ReyesWhy Highly Potent Peptides Can Succeed with Low Oral Bioavailability
By Tom ReyesThe Truth About Oral Peptide Delivery in 2026
By Tom ReyesNURS: A 50-state B2B healthcare platform scales on license growth and peptide-regulatory tailwinds
By Tom ReyesJennifer Woodward's New Book Debunks Peptide Myths for Women's Health
By Tom ReyesMelex Technologies Inc. Launches Simple Life Science, a Life Science Company Supplying Peptide and Small Molecule API and Custom Synthesis to Laboratories
By Tom ReyesUnderstanding Glucagon Like Peptides: Their Role and Medical Uses
By Tom ReyesPolyPeptide Shareholders Approve Board Overhaul and Removal of Transfer Restrictions Ahead of Samsung Biologics Takeover
By Tom ReyesPolyPeptide announces results of the extraordinary general meeting of shareholders
By Tom ReyesHow Lipid-Based Softgels Protect Oral Peptides from Degradation
By Tom ReyesNovel protein and peptide therapeutics
By Tom ReyesViking Therapeutics reports Q3 results October 28 after launching oral VK2735 Phase 3
By Tom ReyesShould Peptide Purification Launch Require Action From DuPont (DD) Investors?
By Tom ReyesCopper Peptide Beauty Products: TheraCopper Launches Skincare and Haircare Collection
By Tom ReyesPeptide Ads: Why Google and Facebook Keep Saying No, and What Gets Approved?
By Tom Reyes
Peptide Sciences Closed: California Trim Clinic Offers Physician-Prescribed Peptide Therapy Options
By Tom ReyesGilead pays nearly $1.3 billion for PepStar oral IL-23 receptor peptide
By Tom ReyesGilead to buy oral IL-23 receptor peptide HCXT-2001 for $1.275 billion
By Tom ReyesImmorta Bio advances nine-amino-acid senolytic peptide against zombie cells
By Tom ReyesVector Science unveils peptide-matrix microneedle platform for transdermal delivery
By Tom ReyesVanta Holdings Inc. (CN:VNTA) Gains 3.75% as Peptide Therapy Expansion, Fresh Financing and Longevity Market Opportunities Lift Investor Optimism
By Tom ReyesPrecision Peptide locks exclusive manufacturing for BPC-157, TA1 patches
By Tom ReyesNovo Nordisk's Buyback and CagriSema Data Address Different Questions Than Its US Problem
By Tom ReyesPrecision Peptide (CNSX:BPC) - Stock Analysis
By Tom ReyesEli Lilly pays METiS TechBio up to $1.1B for lipid nanoparticle work
By Tom ReyesEli Lilly shares weekly forecast: Strong demand for obesity drugs supports sustained gains
By Tom ReyesBet on This New GLP-1 ETF to Gain Exposure to a Booming Market
By Tom ReyesNovo Nordisk targets mid-2027 India launch for oral semaglutide
By Tom ReyesDarling Ingredients Introduces Nextida® NxCogni™, the First Targeted Collagen Peptide Designed to Support Clarity and Cognitive Resilience
By Tom ReyesPeptide Stocks in Focus After HHS Policy Shift as Peptide Swap (PEPS) Bets on a Peptide Crypto Marketplace
By Tom ReyesProGlow Labs Launches Eight Peptide-Based Skincare and Hair Care Formulas
By Tom ReyesREX Shares launches peptide ETF on Nasdaq under ticker PEPT
By Tom ReyesAdaptogenics Health sets peptide strategy targeting metabolic health and aging
By Tom ReyesVanta closes second tranche of private placement financing
By Tom ReyesAdipotide: Investigating a Targeted Peptide Platform for Metabolic and Vascular Research
By Tom ReyesDataMeds unit Corexa lines up peptide suppliers ahead of FDA compounding policy
By Tom ReyesSamsung Biologics declares PolyPeptide tender offer successful
By Tom ReyesREX launches peptide ETF reaching beyond GLP-1 drugmakers
By Tom ReyesAdaptogenics Health names Antoun Nabhan president to build peptide pipeline
By Tom ReyesSamsung Biologics nears $2 billion takeover of PolyPeptide
By Tom ReyesZealand Pharma licenses Generate Biomedicines AI platform for metabolic proteins
By Tom ReyesSamsung Biologics clears takeover threshold with 87.88% of PolyPeptide tendered
By Tom ReyesSamsung Biologics clears tender threshold for peptide maker PolyPeptide
By Tom ReyesSamsung Biologics clears minimum threshold in PolyPeptide tender offer
By Tom ReyesSamsung Biologics clears tender threshold to acquire PolyPeptide Group
By Tom Reyes
